A B S T R A C T
A B S T R A C T To characterize the cell(s) responsible for the suppressor-cell dysfunction in active systemic lupus erythematosus (SLE), we fractionated blood mononuclear cells into thymus-derived (T), bone marrow-derived (B), and monocyte-depleted populations. Various cell populations from active SLE, inactive SLE, or normals, were activated with Concanavalin A, washed, and then co-cultured with active SLE cells. Soluble immune response suppressor (SIRS) from culture supemates of the activated cells was also used for the possible correction of the suppressor-cell dysfunction. Suppression was tested by enumerating DNA-binding cells by radioautography and by quantitating anti-DNA antibody in culture supernates by radioimmunoassay; and immunoglobulin was tested in cells and supernates by the immunofluorescence and the immunofluor techniques, respectively. Except for the numbers of DNA-binding cells, which were not suppressed, all the other three parameters in cocultures with cells from active SLE patients were suppressed by Concanavalin A-activated cells (P < 0.001), or by SIRS (P < 0.05) from normals or inactive SLE patients. Concanavalin A-activated autologous or allogeneic active SLE cells and nonactivated cells from active or inactive SLE failed to suppress the various B-cell functions. Nonactivated normal cells suppressed levels of anti-DNA and immunoglobulin in supernates (P <0.05).
In characterizing the cells responsible for the suppressor dysfunction, it was clear from the results that T cells responsive to Concanavalin A activation are deficient in active SLE and fail to generate SIRS. On the other hand, monocytes from active SLE patients
INTRODUCTION
In normal states there is ample evidence which indicates that autoreactive cell clones (DNA-binding or thyroglobulin-binding cells) are present in the peripheral blood in small numbers (1) . In autoimmune states, expansion of these autoreactive clones has been postulated (2, 3) and shown (4) to be a result of abnormal immunoregulation secondary to suppressor-cell dysfunction.
In active states of human systemic lupus erythematosus (SLE)' we demonstrated suppressor-cell dysfunction, which was reversible and became normal when the disease remitted (4) . In the NZB/W mouse model of SLE, suppressor thymus-derived (T)-cell deficiency was demonstrated early in life and became progressive during the short life span of the animals (5). Though the animals were deficient in suppressor cells, they could respond to suppressor signals from normal mice (6) .
Mouse (7, 8) and human (9) suppressor T cells can be activated by their in vitro incubation with concanavalin A (Con A). Activated suppressor cells secrete a soluble factor called soluble immune response suppressor (SIRS) (10) . The latter was demonstrated to suppress various in vitro immune parameters (11) and was recently demonstrated to be capable of correcting the various autoimmune phenomena in the NZB/W mouse when injected repeatedly before the onset of the disease (6).
l Abbreviations used in this paper: Con A, concanavalin A; SIRS, soluble immune response suppressor; SLE, systemic lupus erythematosus.
In this study we have attempted to identify the cell(s) in human SLE responsible for the suppressor-cell dysfunction and to correct it in vitro by coculturing SLE cells with Con A-activated SLE 
METHODS
Patients and immunologic workup. 14 patients with documented SLE, and who satisfied the diagnostic criteria of the American Rheumatism Association for SLE (12) were studied. This study was approved by the institution's human experimentation committee and informed consents were obtained from all the patients who entered the study. Details of the main clinical and serological features are shown in Table I . Seven patients were studied twice, when their disease was active and again during clinical remission. Disease activity was determined by a rise in sedimentation rate, fever, and increased symptoms together with a drop in serum complement or increase in serum anti-native DNA antibody. None of the patients were on cytotoxic drugs. Prednisone dose received by the patients at the time of study is shown in Table I , with a mean of 35 and 10 mg/day in the active and inactive groups,.respectively. Two control groups were studied, patients and normals. One patient group included four cases of biopsy-proven polyarteritis nodosa on a mean dose of 37.5 mg oral prednisone. These four patients had active disease as manifested by increased erythrocyte sedi- (14) . In seven experiments, mononuclear cells were fractionated into enriched T-(>95%), enriched B-(>87%), and monocyte-depleted (<2%) populations as described by us earlier (4, 15) . Briefly, B-and T-cell fractionation was achieved by the E-rosette centrifugation method (4) . Monocytes were depleted by allowing mononuclear cells to phagocytose iron filings followed by magnet depletion (15) . In five experiments, monocytes were depleted by allowing them to stick to a plastic surface on a Petri dish (no. 3002, Falcon Plastics, Oxnard, Calif.) for 2 h at 37°C. The unattached cells were washed gently and decanted. The attached cells were then recovered by scraping with a rubber spatula. The purity of the various fractions was tested by the E-rosette technique for T cells (4), surface membrane immunoglobulin for B-cells (4), and nonspecific esterase for monocytes (15) .
Various cell fractions and unfractionated cells were washed three times and then incubated for 1 h at 37°C in medium RPMI-1640 (Grand Island Biological Co., Grand Island, N. Y.) in the absence of serum and then washed three times. This allowed shedding and removal of any passively adsorbed antibody (4) . In four experiments, 1 ml of the last wash of cells from the active SLE patients was tested for the presence of immunoglobulin (Ig)G and anti-DNA antibodies; none was detected. 2 x 106 mononuclear cells were cultured in tubes (no. 2001, Falcon Plastics) which contained 1 ml medium RPMI-1640, 20% fetal calfserum (Microbiological Associates, Walkersville, Md.), and various doses (2, 20, and 60 ,Lg) of Con A. Cells were cultured for 48 h at 37°C in a humidified atmosphere of 5% CO2 and 95% air. Control tubes to which no Con A was added were processed the same way. After the incubation period, both cells and supernates were harvested. The cells were washed three times and then tested for suppressor activity. In five experiments, separate tubes were treated with 3H-Con A (New England Nuclear, Boston, Mass.), and the amouht of radioactivity carried by the cells after the 48-h culture and washing procedure was calculated and found to be <3.4% (<68 ng Con A) of the amount added at the initiation of the culture. 60 ng of Con A was added to the non-Con A-activated control cells (to control for the residual Con A left on the Con A-activated cells).
The culture supernates were adsorbed three times with equal volumes of packed Sephadex G-50 (Pharmacia Fine Chemicals, Inc.) for 1 h at 4°C, sterilized, and stored at -700C. The volume used for the s-uppressor assay was expressed as a fraction of 1 ml of the SIRS raised by 2 x 106 cells. Control supernates raised in the absence of Con A were handled and adsorbed in an identical fashion to SIRS. The amount of Con A remaining in the supernate after repeated adsorption with Sephadex was monitored in five experiments with 3H-Con A and was found to be <2.2% (<44 ng Con A) of the added Con A. 40 ng was added to the control supemates to control for the residual Con A in the SIRS.
Testing for suppressor activity of cells or SIRS. 1 X 106 Con A-activated or non-Con A-activated washed cells, or 0. 1-1.0 ml SIRS obtained from Con A-activated or non-Con Aactivated (control) cultures were used. These were co-cultured with 1 x 106 fresh, autologous or allogeneic mononuclear cells obtained from active SLE patients or from controls. The culture conditions were as described by us earlier (4). Briefly, 2 x 106 cells/tube were cultured in 2 ml medium RPMI-1640 and 15% fetal calf serum to which was added 100 Ag pokeweed mitogen (Grand Island Biological Co.).
Controls were 1 x 106 cells of each cell type cultured alone in the presence of pokeweed mitogen. The tubes were incubated for 7 days and then cell supernates were tested for 3H-DNA-binding by the Millipore filter assay (13) as described by us earlier (4) and for immunoglobulin content with immunofluor kits (Bio-Rad Laboratories, Richmond, Calif.).
In all the assays performed for DNA or immunoglobulin in either cells or supemates, the values obtained from cell cultures of suppressor (Con A-or non-Con A-activated) cell types alone were subtracted from values of the cocultures. DNA to be 0.5-ml. A dose of 0.1 ml was ineffective and 1.0 ml was as effective as 0.5 ml.
As can be seen in Table VI , 0.5 ml SIRS of Con Aactivated cells from either inactive SLE or normal donors was capable of inducing significant suppression (P < 0.05) of active SLE cutures. The only exception was the inability of SIRS from the same sources to suppress 3H-DNA binding to cells. SIRS (4) .
In Table VII 7) .
DISCUSSION
The pathogenesis of the autoimmune abnormalities in human SLE and the NZB/W mouse model has been clarified recently by the discovery of T-cell suppressor dysfunction (4, 5, 17, 18) . The expansion and(or) activation of the autoreactive clones (19, 20) may be a result of abnormal immunoregulation secondary to the suppressor cell abnormality (2, 3, 21) . Normal healthy people have few autoreactive clones which are kept under strict control by active normal suppressor cells which prevent their autodestructive capability.
The observation from several laboratories that Con A can activate suppressor cells (7, 8) which secrete suppressor factors has opened a new tool for the possible correction of the T-cell suppressor dysfunction in autoimmunity.
In this report we have shown that immunoglobulin and anti-DNA secretion by active SLE cells can be inhibited by Con A-activated cells or SIRS obtained The cause(s) of suppressor cell dysfunction in SLE is unknown. Viral infections (22, 23) , anti-T-cell antibody (24, 25) or antimonocyte antibody (26), could be possible mechanisms for qualitatively altering T-cell function. It is also unclear whether the T-cell suppressor dysfunction precedes or follows the autoimmune B-cell hyperactive state. In the NZB/W animal model, suppressor dysfunction seems to precede the autoimmune state (5, 18) .
Further clarification of the mechanism by which suppressor cells or SIRS regulate autoreactive clones may lead to specific immunoregulation as a tool in the management of active SLE. Induction of suppressor T cells in SLE by thymosin and cultured thymic epithelium has recently been reported (27) . These therapeutic modalities are nonspecific and, therefore, the possibility of suppressing normal clones that may be important in host defense mechanisms against infections (28) and tumors (29, 30) would have to be carefully studied before in vivo application is considered.
